Isatuximab and Iberdomide As Immunotherapy for High Risk in Smouldering Myeloma
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Dexamethasone (Primary) ; Iberdomide (Primary) ; Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MODIFY
- 16 Jan 2025 New trial record